检索结果-南通市图书馆

A phase Ib/II study of fruquintinib in combination with paclitaxel as the second-line therapy for advanced gastric cancer

引用

Cancer Communications 2023年第1期43卷 150-153页

作者： Yang Zhang Zi-XianWang Lin Shen Jin Li Jing Huang Wei-Guo Su Dong-Sheng Zhang Rui-Hua Xu Department of Clinical Research Sun Yat-Sen University Cancer CenterState Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineGuangzhouGuangdongChina Department of Medical Oncology Sun Yat-Sen University Cancer CenterState Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineGuangzhouGuangdongP.R.China Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer Chinese Academy of Medical SciencesGuangzhouGuangdongP.R.China Department of Gastrointestinal Oncology Beijing Cancer HospitalBeijingP.R.China Department of Medical Oncology Fudan University Shanghai Cancer CenterShanghai Medical CollegeShanghaiP.R.China Department of Medical Oncology Cancer Hospital Chinese Academy of Medical SciencesBeijingP.R.China hutchmed limited ShanghaiP.R.China

Dear Editor,In the first-line setting for advanced gastric cancer(AGC),a combination of nivolumab and fluoropyrimidine/platinum has become the standard treatment[1].However,treatment options are limited after failure of first-line therapy,particularly in ***,a monoclonal antibody against vascular endothelial growth factor receptor(VEGFR)-2,was associated with significant improvements in progression-free survival(PFS)when combined with paclitaxel in the second-line setting[2,3].Further,ramucirumab has not yet been approved by the National Medical ProductsAdministration;hence,it is still inaccessible in ***,single-agent paclitaxel is still a standard-of-care second-line treatment for AGC in China.

关键词： cancer China. gastric

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Baseline radiologic features as predictors of efficacy in patients with pancreatic neuroendocrine tumors with liver metastases receiving surufatinib

引用

Chinese Journal of Cancer Research 2023年第5期35卷 526-535页

作者： Jianwei Zhang Haibin Zhu Lin Shen Jie Li Xiaoyan Zhang Chunmei Bai Zhiwei Zhou Xianrui Yu Zhiping Li Enxiao Li Xianglin Yuan Wenhui Lou Yihebali Chi Nong Xu Yongmei Yin Yuxian Bai Tao Zhang Dianrong Xiu Jia Chen Shukui Qin Xiuwen Wang Yujie Yang Haoyun Shi Xian Luo Songhua Fan Weiguo Su Ming Lu Jianming Xu Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing) Department of Gastrointestinal OncologyPeking University Cancer Hospital&InstituteBeijing 100142China Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing) Department of RadiologyPeking University Cancer Hospital&InstituteBeijing 100142China State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers Beijing Key Laboratory of Carcinogenesis and Translational ResearchDepartment of Gastrointestinal OncologyPeking University Cancer Hospital&InstituteBeijing 100142China Department of Medical Oncology Peking Union Medical College HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100730China Department of Gastric Surgery State Key Laboratory of Oncology in South ChinaCollaborative Innovation Centre for Cancer MedicineSun Yat-sen University Cancer CenterGuangzhou 510062China Department of Pancreatic and Hepatobiliary Surgery Fudan University Shanghai Cancer CenterShanghai 200032China Department of Abdominal Oncology West China HospitalSichuan UniversityChengdu 332001China Department of Medical Oncology the First Affiliated Hospital of Xi’an Jiaotong UniversityXi’an 710061China Department of Oncology Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430030China Department of General Surgery Zhongshan Hospital of Fudan UniversityShanghai 200032China Department of Medical Oncology National Cancer Center/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China Department of Medical Oncology the First Affiliated Hospital of Zhejiang UniversityHangzhou 310009China Department of Medical Oncology the First Affiliated Hospital of Nanjing Medical UniversityNanjing 210029China Department of Gastrointestinal Oncology Harbin Medical University Cancer HospitalHarbin 150081China Department of Oncology Union HospitalTongji Medical

Objective:Currently,pre-treatment prediction of patients with pancreatic neuroendocrine tumors with liver metastases(PNELM)receiving surufatinib treatment was *** objective was to examine the association between radiological characteristics and efficacy/***:We enrolled patients with liver metastases in the phase III,SANET-p trial(NCT02589821)and obtained contrast-enhanced computed tomography(CECT)*** and quantitative parameters including hepatic tumor margins,lesion volumes,enhancement pattern,localization types,and enhancement ratios were *** progression-free survival(PFS)and hazard ratio(HR)were calculated using Cox’s proportional hazard *** was analyzed by logistic-regression ***:Among 152 patients who had baseline CECT assessments and were included in this analysis,the surufatinib group showed statistically superior efficacy in terms of median PFS compared to placebo across various qualitative and quantitative *** the multivariable analysis of patients receiving surufatinib(N=100),those with higher arterial phase standardized enhancement ratio-peri-lesion(ASER-peri)exhibited longer PFS[HR=0.039;95%confidence interval(95%CI):0.003−0.483;P=0.012].Furthermore,patients with a high enhancement pattern experienced an improvement in the objective response ratio[31.3%vs.14.7%,odds ratio(OR)=3.488;95%CI:1.024−11.875;P=0.046],and well-defined tumor margins were associated with a higher disease control rate(DCR)(89.3%vs.68.2%,OR=4.535;95%CI:1.285−16.011;P=0.019)compared to poorlydefined ***:These pre-treatment radiological features,namely high ASER-peri,high enhancement pattern,and well-defined tumor margins,have the potential to serve as predictive markers of efficacy in patients with PNELM receiving surufatinib.

关键词： Neuroendocrine tumors liver metastases computed tomography surufatinib

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：